Company Overview

Nexalin Technology, Inc. is a medical technology company focused on the development and commercialization of non-invasive neuromodulation therapies for mental health and neurological conditions. The company operates within the medical devices and mental health technology industries, with an emphasis on bioelectronic medicine that modulates brain activity without the use of pharmaceuticals. Its core mission is to provide scalable, non-drug alternatives for conditions such as anxiety, depression, insomnia, and substance use disorders.

The company’s primary revenue driver is the development and planned commercialization of its proprietary neuromodulation systems, most notably the Gen-2 Nexalin Device, which is designed for home and clinical use. Nexalin positions itself as a differentiated provider by offering a wearable, non-invasive, and drug-free therapy that targets neural oscillations through low-level electrical stimulation. Nexalin Technology, Inc. was founded in 2016 and completed a reverse merger to become a publicly traded company in 2022, subsequently listing its shares on the Nasdaq Capital Market under the ticker NXL.

Business Operations

Nexalin operates as a single-reportable-segment company focused on neuromodulation device research, regulatory clearance, and commercialization. Its operations include device engineering, clinical research, regulatory strategy, and early-stage commercialization efforts. Revenue to date has been limited, as the company remains in the pre-commercial and early commercialization phase, with activities largely funded through equity financing rather than product sales.

The company controls proprietary neuromodulation technology and associated intellectual property, including patents related to waveform delivery and device architecture. Nexalin does not currently operate manufacturing facilities at scale and relies on third-party manufacturers and research partners. The company has conducted clinical studies in the United States and internationally and has worked with academic and clinical institutions to evaluate the efficacy of its devices. No material joint ventures have been disclosed, and Nexalin operates primarily through its wholly owned operating subsidiary, Nexalin Technology, Inc.

Strategic Position & Investments

Nexalin’s strategic direction centers on advancing regulatory pathways, expanding clinical validation, and entering large addressable mental health markets with a non-pharmaceutical alternative. Key growth initiatives include pursuing U.S. Food and Drug Administration clearance for additional indications, expanding international regulatory approvals, and transitioning from research-stage deployment to commercial sales channels, including clinics and direct-to-consumer models.

The company has not completed any major acquisitions as of the most recent public filings. Investment activity has primarily focused on internal research and development, clinical trials, and intellectual property protection. Nexalin is positioned within emerging sectors such as digital therapeutics and bioelectronic medicine, targeting patient populations underserved by traditional pharmacological treatments. Public disclosures do not indicate ownership of a diversified portfolio of subsidiaries or minority investments.

Geographic Footprint

Nexalin is headquartered in Houston, Texas, and its executive leadership, research coordination, and corporate functions are primarily based in the United States. The company’s clinical research activities have included both domestic and international study sites, reflecting an effort to support regulatory strategies outside the U.S.

Internationally, Nexalin has reported clinical and commercial interest in Asia, particularly China, where the company has pursued regulatory pathways and distribution discussions for its neuromodulation technology. While Nexalin does not maintain a large physical operational footprint abroad, its strategy includes leveraging international partnerships and regulatory approvals to expand global market access over time.

Leadership & Governance

Nexalin is led by a management team with experience in healthcare, technology commercialization, and corporate finance. The leadership emphasizes a strategy centered on evidence-based innovation, regulatory discipline, and scalable mental health solutions that reduce reliance on pharmaceuticals. Governance follows standard public company practices, with oversight provided by a board of directors.

Key executives include:

• Mark White – President, Chief Executive Officer, and Director
• Mark Troutman – Chief Financial Officer
• Patrick C. Fagan – Chief Technology Officer
• Scott D. Box – Chief Operating Officer

The leadership team’s stated vision focuses on advancing non-invasive neuromodulation as a mainstream treatment option and positioning Nexalin as a clinically credible and commercially viable mental health technology company.